Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Rabbit Monoclonal Antibodies Now Available for Use in Cancer-Related Research

By BiotechDaily International staff writers
Posted on 08 Aug 2011
Cancer researchers now have access to 23 novel, cancer-related rabbit monoclonal antibodies that have been released to the commercial market.

The antibodies are the fruit of cooperation between the [US] National Cancer Institute (Bethesda, MD, USA) and the biotechnology company Epitomics, Inc. (Burlingame, CA, USA). Epitomics has developed a unique and proprietary method for making monoclonal antibodies from rabbits rather than the conventional method of starting with mice.

The basic principal for making the antibody is the same as for mouse monoclonal antibodies. Proprietary rabbit fusion-partner cells fuse to rabbit B-cells to create rabbit hybridoma cells. Hybridomas are then screened to select for clones with specific and sensitive antigen recognition, and the antibodies are characterized using a variety of methods. The rabbit immune system generates antibody diversity and optimizes affinity by mechanisms that are more efficient than those of mice and other rodents. This increases the possibility of obtaining a functional antibody that will work in a variety of applications.

This technology - combined with the expertise of researchers at the National Cancer Institute – has produced a line of 23 rabbit monoclonal antibodies that should be of use to cancer investigators. The antibodies are available for purchase in the United States directly through Epitomics and around the world through Epitomics’ international distributors. The collaborators plan to develop another 20 antibodies for commercial release over the next two years.

“We are very excited to see the progress we have made in developing several key antibodies with National Cancer Institute investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies,” said Dr. Guo-Liang Yu, CEO of Epitomics, Inc.

Related Links:

National Cancer Institute
Epitomics, Inc.



Channels

Drug Discovery

view channel
Image: Wafers like the one shown here are used to create “organ-on-a-chip” devices to model human tissue (Photo courtesy of Dr. Anurag Mathur, University of California, Berkeley).

Human Heart-on-a-Chip Cultures May Replace Animal Models for Drug Development and Safety Screening

Human heart cells growing in an easily monitored silicon chip culture system may one day replace animal-based model systems for drug development and safety screening. Drug discovery and development... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

“Softer” Mass Spec Techniques Gain Advantage in Biomarker Discovery

Two mass spectrometry (MS) technologies, MALDI and DESI, are increasing in applications as their effectiveness is established, according to Kalorama Information (New York, NY, USA) in its report “Proteomics Markets for Research and IVD Applications (Mass Spectrometry, Chromatography, Microarrays, Electrophoresis, Immunoassays,... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.